Jula Inrig, M.D., serves as the Chief Medical Officer at Travere Therapeutics Inc., a biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for rare diseases. Dr. Inrig brings a wealth of experience in nephrology and clinical development to her role, having spent over a decade in the pharmaceutical industry. Prior to joining Travere Therapeutics, she held significant positions at Gilead Sciences, where she was the Vice President of Clinical Research for Nephrology, and at Amgen, where she served as the Executive Medical Director. Dr. Inrig's professional journey is marked by her dedication to advancing treatments for kidney diseases. She completed her medical degree at the University of Toronto and pursued her residency and fellowship in nephrology at Duke University Medical Center. Her academic contributions include numerous publications in peer-reviewed journals, focusing on chronic kidney disease and related therapies. Her work at Gilead Sciences was instrumental in the development of treatments for kidney-related conditions, showcasing her ability to lead clinical research programs effectively. As Chief Medical Officer at Travere Therapeutics, Dr. Inrig plays a pivotal role in steering the company's clinical development strategy. Her leadership is crucial in overseeing the advancement of the company's pipeline, which includes therapies aimed at rare kidney and metabolic disorders. Under her guidance, Travere Therapeutics continues to make strides in bringing innovative treatments to patients with unmet medical needs, reinforcing the company's commitment to transforming the lives of those affected by rare diseases.